Compass Pathways to Engage in September Investor Conferences
Upcoming Investor Conferences for Compass Pathways
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company devoted to enhancing patient access to transformative mental health solutions, is set to engage in a series of prominent investor conferences this September. These events offer a platform for the company's management to discuss their cutting-edge approaches in the mental health arena and to connect with current and potential investors.
Key Conference Details
The following events are on the agenda for Compass Pathways this September:
- Morgan Stanley 22nd Annual Global Healthcare Conference: Management will participate in a fireside chat on September 4, with a start time of 7:45 am ET, alongside hosting investor meetings.
- H. C. Wainwright 26th Annual Global Investment Conference: A fireside chat is scheduled for September 10 at 9:30 am ET, plus additional opportunities for investor meetings.
- Cantor Global Healthcare Conference: This will feature a fireside chat on September 17 at 2:30 pm ET, along with hosting investor meetings.
Participants will have access to a live audio webcast of these events, which can be found on the "Events" page in the Investors section of the Compass website. Furthermore, a replay of each webcast will be available for 30 days following each event for those unable to attend live.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) strives to improve the lives of individuals grappling with mental health issues that are inadequately addressed by current treatment protocols. The company is pioneering a new model of psilocybin treatment utilizing its proprietary formulation called COMP360. This innovative treatment combines synthetic psilocybin administration with necessary psychological support, demonstrating the potential to revolutionize mental health treatment.
Innovative Treatments and Clinical Programs
COMP360 has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK specifically for treatment-resistant depression (TRD). This emphasizes the significance and promise of Compass Pathways' approaches.
Currently, a critical phase 3 clinical program is underway, representing the largest randomized, controlled, double-blind psilocybin treatment study ever performed, focusing on TRD. Prior to this, the company successfully conducted a phase 2b study which revealed a statistically significant and clinically meaningful reduction in depressive symptoms after just three weeks among participants who received a single dose of 25mg of COMP360 with psychological support.
Moreover, Compass Pathways has completed an open-label phase 2 study focusing on COMP360 for post-traumatic stress disorder (PTSD) and is now advancing a phase 2 study targeting anorexia nervosa. The breadth of ongoing research highlights the company’s commitment to addressing various mental health challenges through innovative treatment options.
Corporate Presence and Vision
Headquartered in London, Compass Pathways also operates offices in New York and San Francisco, emphasizing a dedicated presence in significant markets. The company's overarching vision promotes a framework for achieving a world characterized by mental wellbeing, seeking to empower those who contend with mental health challenges.
Investor Communication Strategy
Compass Pathways actively communicates with investors and the public through a variety of channels. Key platforms include their primary website, an investor relations site, and social media outlets. The company regularly posts updates such as investor presentations, SEC filings, and press releases to ensure stakeholders are well-informed about its operations and advancements in treatment methodologies.
For inquiries or further information, interested parties can reach out to the appropriate contacts:
Media Contact: Sally Bain, media@compasspathways.com, +1 781 458 0443
Investor Contact: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Frequently Asked Questions
What is Compass Pathways plc known for?
Compass Pathways plc is known for its innovative approaches to treating mental health disorders, particularly its work on psilocybin treatments.
Where will the upcoming conferences take place?
The upcoming investor conferences will be accessible through live audio webcasts on the Compass Pathways website.
What is COMP360?
COMP360 is Compass Pathways’ proprietary formulation of synthetic psilocybin used in conjunction with psychological support to treat mental health disorders.
What designations has COMP360 received?
COMP360 has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway designation in the UK.
How can I stay updated about Compass Pathways?
You can stay updated by following the company’s website, investor relations page, and their social media channels for the latest news and updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- X4 Pharmaceuticals to Present at September Investor Conferences
- Keros Therapeutics to Present at Key Healthcare Conferences
- Cabaletta Bio to Attend Key Investor Conferences
- Avadel Pharmaceuticals Upcoming Investor Conference Participation
- Liquidia Corporation to Showcase Innovations at Investor Conferences
- Pliant Therapeutics Engages Investors in September Events
- Alignment Healthcare to Participate in Baird Conference
- Intra-Cellular Therapies CEO to Present at Major Conferences
- CF Energy Releases Q2 and 1H 2024 Financial Results
- Exploring Shopify and Cloudflare Growth Potential